The TTN-AS1 axis has also been reported to be tumor-promoting in a variety of cancers including prostate cancer, HCC, and breast cancer [37–39], and a decrease in its activity can inhibit tumor aggressiveness. Here, TTN is linked to hepatocellular carcinoma.